Previous 10 | Next 10 |
– Company separation completed on November 4, 2021 – bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2021. “This quarter was about preparing for the completion of th...
New headquarters designed to reflect modern ways of working and deliver significant cost savings bluebird bio, Inc . (NASDAQ: BLUE) announced today that it has signed a long-term lease with Federal Realty (Federal) to establish a biotech hub at Assembly Row. The ...
bluebird bio (BLUE +1.2%) has completed the planned spinoff of cell therapy company 2seventy bio (TSVT), which will begin trading on Nasdaq tomorrow. 2seventy's portfolio includes Abecma (idecabtagene vicleucel), a gene therapy approved earlier this year for multiple myeloma. The company says...
Oral presentation of long-term results for betibeglogene autotemcel gene therapy (beti-cel) in adult, adolescent, and pediatric patients with beta-thalassemia who require regular red blood cell transfusions; data for up to seven years follow-up selected for ASH press program N...
Company to focus on gene therapies for severe genetic diseases Three near-term programs positioned to deliver significant commercial and patient impact Spotlight investor call on bb1111 product candidate for sickle cell disease scheduled for November 18 b...
bluebird bio is preparing to spin off their cell therapy into a new publicly traded company, 2seventy bio. bluebird will focus on the company's gene therapy products. Although I am still fairly bullish on both tickers, I am concerned about where the market is going to take BLUE once t...
bluebird bio was a pioneer in the gene therapy space. Unfortunately, it hasn't been a commercial success. The upcoming spinoff doesn't raise confidence in bluebird's future either. For further details see: bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea
What do AbbVie , Bristol Myers Squibb , and AstraZeneca all have in common? All three are among the largest pharma companies in the world. But all of these drugmakers have also closed high-profile acquisitions within the past two years. These deals helped them bolster their...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s upcoming IPOs this week that traders are going to want to keep an eye on and we’re helping with a handy list. Source: Shutterstock Initial public offerings (IPOs) seeing companies offering up sha...
bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two ind...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...